Business NewsPR NewsWire • AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

NORTH CHICAGO, Ill. and BREDA, The Netherlands and GHENT, Belgium, April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated...

View More : http://www.prnewswire.com/news-releases/abbvie-and-argenx-to-collaborate-on-argx-115-against-novel-immuno-oncology-targe...
Releted News by prnewswire
Heavy Rockets brings classic arcade shooter action to iOS
AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target
Immigration Policy and the Politics of Bernie Sanders